Financials in USD. Standardized financial statements.
A compact view of how Prometheus Biosciences, Inc. turns revenue into operating income and net income.
| Metric | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2016 | FY 2015 | FY 2014 |
|---|---|---|---|---|---|---|---|
| Revenue? | $6.81M | $3.13M | $1.23M | $1.12M | $0 | $0 | $150,000 |
| Revenue Growth? | +117.6% | +154.6% | +9.9% | 0.0% | 0.0% | -100.0% | 0.0% |
| Cost of Revenue? | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross Profit? | $6.81M | $3.13M | $1.23M | $1.12M | $0 | $0 | $150,000 |
| Gross Margin? | +100.0% | +100.0% | +100.0% | +100.0% | 0.0% | 0.0% | +100.0% |
| Operating Expenses? | $152.59M | $90.93M | $30.24M | $17.09M | $100.68M | $90.58M | $40.00M |
| Operating Income? | -$145.78M | -$87.80M | -$29.01M | -$15.97M | -$100.68M | -$90.58M | -$39.85M |
| EBITDA? | -$145.15M | -$89.08M | -$28.90M | -$15.92M | -$96.95M | -$87.83M | -$39.45M |
| Income Before Tax | -$141.75M | -$90.19M | -$31.14M | -$16.73M | -$103.64M | -$92.46M | -$39.98M |
| Income Tax Expense | $0 | -$258,000 | $8.11M | $13.76M | $259,000 | $715,000 | $12,330 |
| Net Income? | -$141.75M | -$89.94M | -$39.25M | -$30.49M | -$103.64M | -$92.46M | -$39.99M |
| EPS? | $-3.49 | $-2.87 | $-1.13 | $-1.13 | $-2.69 | $-3.44 | $-2.18 |
| Diluted EPS? | $-3.49 | $-2.87 | $-1.13 | $-1.13 | $-2.69 | $-3.44 | $-2.18 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality